Scientific Online Resource System

Scripta Scientifica Medica

Fetal fibronectin FFN. Biochemical markers of preterm birth

Nikolai Kolev, Stephan Ivanov, Emil Kovachev, Stanislav Slavchev


The use of biochemical markers for predicting preterm birth has a potential advantage because it provides direct evidence of changes in the extracellular matrix of the surface between fetal membranes and decidual tissue.  [1, 12] fFN is a protein that is produced during pregnancy and acts as a biological glue such as the amniotic sac kept attached to the endometrium. fFN can be found in cervico-vaginal secretions up to 22 weeks and late in the last trimester. [7] The purpose of this study is to determine the level of fetal fibronectin (fFN) in cervical mucus as a specific indicator of preterm birth in pregnant women with clinical symptoms. The study was attended by 90 women divided into two groups. First group of pregnant women at term gestation 24-34 weeks with clinical symptoms the PB and the second group of pregnant women with normal pregnancy occurs. In all women was conducted Full Term Test. The results were statistically processed by using SPSS v. 17. The presence of symptoms of preterm labor showed difference in the percentage of positive results of fFN test (p <0.05), women with clinical symptoms have - a high percentage of positive tests. When conducting Full term pregnancy test with positive results in the highest percentage with overt clinical RTD, Roma and second and third birth. Furthermore, pregnant women with a positive test result mainly born at 35 weeks, newborns weighed an average of 2 550.1 g, which explicitly includes them in the premature population.


fFN; preterm birth; biochemical marker; full term test; risk factors; a positive result

Full Text


ACOG news release October 31, 2003: Progesterone recommended in certain high risk

pregnancies to help prevent preterm birth.

American College of Obstetrics and Gynecologists (ACOG). Assessment of Risk

Factors for Preterm Birth. ACOG Practice Bulletin, number 31, October 2001 (reaffirmed 2008).

Andersen HF. Use of fetal fibronectin in women at risk for preterm delivery. Clin Obstet Gynecol 2000; 43: 746-758.

Ascarelli MH, Morrison JC. Use of fetal fibronectin. Obstet Gynecol Surv 1997, 52: 1-12.

Bashore RA, Westlake JR. Plasma values of unconjugated estriol in high-risk pregnancy. Am J Obstet Gynecol 1997; 128: 371-80.

Berghella, V., et al. Fetal Fibronectin Testing for Reducing the Risk of Preterm Birth (Review). The Cochrane Library, 2009, Issue 2.

Goldenberg R.L., J.F. Culhane, J.D. Iams, et al. Epidemiology and causes of preterm birth. Lancet, 2008; 5; 371(9606): 75-84.

Honest H., L.M. Bachman, J.K. Kleijnen, K.S. Khan. Accuracy of cervico-vaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ, 2002; 325:301-320.

Malinova M., Clinical behavior cervix. Midwifery and gynecology. Obstet and Gynecol, 2013; 1:41-48.

Meis P., Klebanoff M., Thom E. et al. Prevention of recurrent preterm delivery by 17 alphahydroxyprogesterone caproat. NEJM, 2003; 348: 2379-2385.

The American College of Nurse-Midwives (ACNM). Division of Standards and Practice

Clinical Standards and Documents Section. Prevention of Preterm Labor and Preterm Birth, June 2012.

Yast J.D., G. Lu. Biochemical markers for the prediction of preterm delivery. Clin Perinatol, 2007 Dec; 34(4):573-586.



Article Tools
Email this article (Login required)
About The Authors

Nikolai Kolev
Medical University of Varna

Department of Obstetrics and Gynecology

Stephan Ivanov
Medical University of Varna

Department of Obstetrics and Gynecology

Emil Kovachev
Medical University of Varna

Department of Obstetrics and Gynecology

Stanislav Slavchev
Medical University of Varna

Department of Obstetrics and Gynecology

Font Size